Citadel Advisors
LXEO icon

Citadel Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Citadel Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,800
Closed -$44.4K – 13995
2025
Q1 		$44.4K Buy
+12,800
New +$56.7K ﹤0.01% 12430

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citadel Advisors's LXEO Position: Q2 2026 in Review

Citadel Advisors increased its Lexeo Therapeutics (LXEO) stake by 1.7% in Q2 2026, buying an estimated $344K and bringing the position to 3,898,570 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2717.

Citadel Advisors first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $41M in Q2 2024. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Citadel Advisors held 3,898,570 shares of Lexeo Therapeutics worth $18.1M as of Q2 2026.
  • Citadel Advisors bought 63,571 Lexeo Therapeutics shares in Q2 2026, an estimated $344K.
  • Lexeo Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2717 holding.
  • Citadel Advisors first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Citadel Advisors's Lexeo Therapeutics position peaked at $41M in Q2 2024.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.